Aducanumab was the first therapy to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer’s disease …

Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [1][2] It is a monoclonal antibody [2][1] that targets aggregated forms …

Oct 27, 2025 · What is aducanumab? Aducanumab is used to treat adults with Alzheimer's disease. Aducanumab may also be used for purposes not listed in this medication guide.

The FDA has approved the medicine aducanumab, for the treatment of Alzheimer’s disease. This is the first new Alzheimer’s drug approved in 18 years and the first therapy that can slow …

Jun 30, 2024 · Aducanumab (Aduhelm) is a discontinued drug for Alzheimer’s disease with mild cognitive impairment. It’s a monoclonal antibody that works by removing amyloid proteins – …

What is aducanumab, and what is it used for? Aducanumab is a medication used in the treatment of Alzheimer’s disease, a progressive brain disease that destroys memory and other mental …

Aug 19, 2025 · Given as an intravenous (into-the-vein) infusion once every four weeks, the treatment’s active ingredient, aducanumab, targets aggregated beta-amyloid, helping to …

Aducanumab-avwa injection is used to reduce amyloid beta plaque, a protein found in the brain of people with Alzheimer's disease (a brain disease that slowly destroys the memory and ability …

FDA approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans, using the Accelerated Approval pathway